EGFR and adenocarcinoma: The PFS in this study was very similar with that in patients treated with gefitinib in IPASS study [2], which enrolled patients with clinical enrichment of EGFR mutation, including East Asian, female, non-smoker or light smoker and adenocarcinoma.